Reduced-intensity conditioning with either of 2 drug combinations leads to superior survival and acceptable non-relapse mortality in patients with follicular lymphoma undergoing allogeneic hematopoietic cell transplantation (allo-HCT), according to a study involving 200 individuals. 1 of the regimens was linked with lower chronic graft-versus-host disease (GVHD).
Participants were given either fludarabine and busulfan (Flu/Bu; n=98) or fludarabine, cyclophosphamide, and rituximab (FCR; n=102) between 2008 and 2014. They also received peripheral blood grafts, as well as calcineurin inhibitors for GVHD prophylaxis. Among the results:
- 3-year non-relapse mortality, relapse/progression, progression-free survival, and overall survival rates were similar in both groups.
- There were also no differences in grade II-IV or grade III-IV acute GVHD.
- Patients taking FCR had a 48% reduced risk of chronic GVHD.
Epperla N, Ahn K, Armand P, et al. Fludarabine and busulfan versus fludarabine, cyclophosphamide and rituximab as reduced-intensity conditioning for allogeneic transplantation in follicular lymphoma. [Published online ahead of print October 13, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.10.011.
Must Reads in Follicular Lymphoma
Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31
Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53
5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262